MedTrace Logo

Risk Communication in African American Smokers

NCT04084561 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 166

Last updated 2023-12-18

Study results available
· View outcomes & findings →

Summary

The study aims to understand the effects of learning about one's genetic risk for lung cancer that is specific to their ancestry. Participants will be given hypothetical personalized genetic risk results and ask to think about how they might respond to such information if they actually received such results.

Conditions

Interventions

BEHAVIORAL

HRHA

participants will be asked to consider a hypothetical scenario in which genetic test results reveal that: 1) they carry genotypes that place African American smokers at a particularly high (\~50%-80%) risk for the development of lung cancer, and 2) their genetic profile reflects a particularly high concordance with African heritage (\~90%).

BEHAVIORAL

LRLA

participants will be asked to consider a scenario in which genetic test results reveal that: 1) they are at normal (\~7%-10%) risk for the development of lung cancer, and 2) their genetic profile reflects a particularly low concordance with African heritage (\~10%).

BEHAVIORAL

HRLA

participants will receive "High Risk, Low Ancestry (HRLA)" hypothetical

BEHAVIORAL

LRHA

participants will receive "Low Risk, High Ancestry (HRLA)" hypothetical

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Temple University

    lead OTHER

Principal Investigators

  • Camille Ragin, PhD · Fox Chase Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2022-04-01
Completion
2022-04-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04084561 on ClinicalTrials.gov